The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis
The findings from this study suggest that a 6 months' treatment course of NP001 resulted in a 4.8-month increase in overall survival in patients with ALS. The findings from this study indicate that targeting inflammation associated with the innate immune system may provide a pathway for new therapeutic options for the treatment of ALS.
Authors
- Ari Azhir
- Michelle Robinson (ORCID: https://orcid.org/0000-0002-4790-8919)
- Bruce D. Forrest (ORCID: https://orcid.org/0000-0001-6183-5165)
- Namita Goyal (ORCID: https://orcid.org/0000-0002-1713-545X)
- Paige M. Bracci (ORCID: https://orcid.org/0000-0001-9338-9307)
- Neil R. Brett (ORCID: https://orcid.org/0000-0002-6175-2535)
- Michael S. McGrath (ORCID: https://orcid.org/0000-0002-7232-2602)
- Thomas R. Fleming (ORCID: https://orcid.org/0000-0002-0420-5068)
- Zaeem Khan (ORCID: https://orcid.org/0000-0002-7286-7194)
Institutions
- Hudson Institute (US)
- University of California, San Francisco (US)
- University of Washington (US)
- University of California, Irvine (US)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3390/biomedicines12102367
- Citations
- 4
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 1.48